CIK: 0001911270
Total reported value
—
Reporting period: 2025-09-30 · Number of holdings: 1
Springhill Fund Asset Management (HK) Co Ltd disclosed 1 holdings in its latest 13F filing for the period ending 2025-09-30, with total reported value of — and a quarterly turnover rate of 0.0%.
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Sold out VRNA
Sold out SMMT
Sold out JANX
Sold out REGN
Sold out NBIX
Sold out INSM
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Ikena Oncology INC | Stock-Other | — | — | — |
Performance for Q3 2026
—
Performance Last 4 Quarters
+6.9%
Based on 55% of reported portfolio value with available pricing
Not enough sector-mapped data yet
Springhill Fund Asset Management (HK) Co Ltd's most significant position changes for 2025-09-30: Sold out: Verona Pharma PLC - Adr (VRNA); Sold out: Summit Therapeutics INC (SMMT); Sold out: Janux Therapeutics INC (JANX); Sold out: Regeneron Pharmaceuticals (REGN); Sold out: Neurocrine Biosciences INC (NBIX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 2 | SMMT | Summit Therapeutics INC | — | EXIT | Sold out |
| 3 | JANX | Janux Therapeutics INC | — | EXIT | Sold out |
| 4 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 5 | NBIX | Neurocrine Biosciences INC | — | EXIT | Sold out |
| 6 | INSM | Insmed INC | — | EXIT | Sold out |
| 7 | SLNOEUR | Soleno Therapeutics INC | — | EXIT | Sold out |
| 8 | JAZZ | Jazz Pharmaceuticals plc | — | EXIT | Sold out |
| 9 | AKRO | Akero Therapeutics INC | — | EXIT | Sold out |
| 10 | ARGX | Argenx Se - Adr | — | EXIT | Sold out |
| 11 | LLY | Eli Lilly & Co | — | EXIT | Sold out |
| 12 | PTGX | Protagonist Therapeutics INC | — | EXIT | Sold out |
| 13 | TGTX | Tg Therapeutics INC | — | EXIT | Sold out |
| 14 | TARS | Tarsus Pharmaceuticals INC | — | EXIT | Sold out |
| 15 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 16 | RYTM | Rhythm Pharmaceuticals INC | — | EXIT | Sold out |
| 17 | BNTX | Biontech Se-adr | — | EXIT | Sold out |
| 18 | SWTXUSD | Springworks Therapeutics INC | — | EXIT | Sold out |
| 19 | COGT | Cogent Biosciences INC | — | EXIT | Sold out |
| 20 | ✓ | Ikena Oncology INC | — | — | Unchanged |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2025-09-30 | 2025-10-09 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-13 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-14 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0000048966
Total reported value
—
1 stks
2024-12-31
Stale — no recent filing
CIK 0000056822
Total reported value
—
1 stks
2019-12-31
Stale — no recent filing
CIK 0000083402
Total reported value
—
1 stks
2021-09-30
Stale — no recent filing